PIPELINE > TRIAL OVERVIEW
KRAS G12C Inhibitor
Olomorasib
- Type of Alteration(s)Point mutationAlteration(s) of InterestKRAS G12C
Methodology
Key Considerations
NGS (Tissue)- Suitable for broad-based genomic profiling that includes targets in addition to KRAS
PCR-based- Will detect selected mutations but may miss novel KRAS alterations
- Selected assay should have full coverage of exon 2
NGS (cfDNA)- Useful when tissue biopsy sample is limited/unavailable
- Higher false negative rate than tissue-based NGS testing
References
- Sherwood JL, et al. ESMO Open. 2017;2(4):e000235.
- Arbour KC, et al. Clin Cancer Res. 2021;27(8):2209-2215.
For information on trial enrollment, locations, and more, call
1-800-545-5979.
or visit www.clinicaltrials.gov for more information on this trial
This website was commissioned by Lilly Medical and is indicated to be used by HCPs for medical, scientific, and educational purposes.
The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent.
